Literature DB >> 22552007

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

J J M van Dongen1, L Lhermitte, S Böttcher, J Almeida, V H J van der Velden, J Flores-Montero, A Rawstron, V Asnafi, Q Lécrevisse, P Lucio, E Mejstrikova, T Szczepański, T Kalina, R de Tute, M Brüggemann, L Sedek, M Cullen, A W Langerak, A Mendonça, E Macintyre, M Martin-Ayuso, O Hrusak, M B Vidriales, A Orfao.   

Abstract

Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on expert opinions, but they have not been validated. Here we present the validated EuroFlow 8-color antibody panels for immunophenotyping of hematological malignancies. The single-tube screening panels and multi-tube classification panels fit into the EuroFlow diagnostic algorithm with entries defined by clinical and laboratory parameters. The panels were constructed in 2-7 sequential design-evaluation-redesign rounds, using novel Infinicyt software tools for multivariate data analysis. Two groups of markers are combined in each 8-color tube: (i) backbone markers to identify distinct cell populations in a sample, and (ii) markers for characterization of specific cell populations. In multi-tube panels, the backbone markers were optimally placed at the same fluorochrome position in every tube, to provide identical multidimensional localization of the target cell population(s). The characterization markers were positioned according to the diagnostic utility of the combined markers. Each proposed antibody combination was tested against reference databases of normal and malignant cells from healthy subjects and WHO-based disease entities, respectively. The EuroFlow studies resulted in validated and flexible 8-color antibody panels for multidimensional identification and characterization of normal and aberrant cells, optimally suited for immunophenotypic screening and classification of hematological malignancies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552007      PMCID: PMC3437410          DOI: 10.1038/leu.2012.120

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  286 in total

1.  Reactive phenotypes after acute and chronic NK-cell activation.

Authors:  M Lima; J Almeida; M A Teixeira; A H Santos; M L Queirós; S Fonseca; J Moura; M Gonçalves; A Orfão; A C Pinto Ribeiro
Journal:  J Biol Regul Homeost Agents       Date:  2004 Jul-Dec       Impact factor: 1.711

2.  Detection of malignant haematopoietic cells in the cerebrospinal fluid by conventional cytology and flow cytometry.

Authors:  Holger Nückel; Jürgen R Novotny; Richard Noppeney; Irini Savidou; Ulrich Dührsen
Journal:  Clin Lab Haematol       Date:  2006-02

3.  Early T-cell precursor acute lymphoblastic leukaemia.

Authors:  Jeffrey W Taub
Journal:  Lancet Oncol       Date:  2009-02       Impact factor: 41.316

4.  Immunophenotypical, morphologic, and functional characterization of maturation-associated plasmacytoid dendritic cell subsets in normal adult human bone marrow.

Authors:  Lourdes Martín-Martín; Julia Almeida; Pilar María Hernández-Campo; María Luz Sánchez; Quentin Lécrevisse; Alberto Orfao
Journal:  Transfusion       Date:  2009-08       Impact factor: 3.157

Review 5.  Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions.

Authors:  A Orfao; G Schmitz; B Brando; A Ruiz-Arguelles; G Basso; R Braylan; G Rothe; F Lacombe; F Lanza; S Papa; P Lucio; J F San Miguel
Journal:  Clin Chem       Date:  1999-10       Impact factor: 8.327

6.  Clonal X-inactivation analysis of human tumours using the human androgen receptor gene (HUMARA) polymorphism: a non-radioactive and semiquantitative strategy applicable to fresh and archival tissue.

Authors:  P Kopp; R Jaggi; A Tobler; B Borisch; M Oestreicher; L Sabacan; J L Jameson; M F Fey
Journal:  Mol Cell Probes       Date:  1997-06       Impact factor: 2.365

7.  Phenotypic difference of normal plasma cells from mature myeloma cells.

Authors:  H Harada; M M Kawano; N Huang; Y Harada; K Iwato; O Tanabe; H Tanaka; A Sakai; H Asaoku; A Kuramoto
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

8.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316

9.  Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA).

Authors:  Luis Escribano; Beatriz Diaz-Agustin; Antonio López; Rosa Núñez López; Andrés García-Montero; Julia Almeida; Aranzazu Prados; Miguel Angulo; Sonia Herrero; Alberto Orfao
Journal:  Cytometry B Clin Cytom       Date:  2004-03       Impact factor: 3.058

10.  Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.

Authors:  Arjan A van de Loosdrecht; Canan Alhan; Marie Christine Béné; Matteo G Della Porta; Angelika M Dräger; Jean Feuillard; Patricia Font; Ulrich Germing; Detlef Haase; Christa H Homburg; Robin Ireland; Joop H Jansen; Wolfgang Kern; Luca Malcovati; Jeroen G Te Marvelde; Ghulam J Mufti; Kiyoyuki Ogata; Alberto Orfao; Gert J Ossenkoppele; Anna Porwit; Frank W Preijers; Stephen J Richards; Gerrit Jan Schuurhuis; Dolores Subirá; Peter Valent; Vincent H J van der Velden; Paresh Vyas; August H Westra; Theo M de Witte; Denise A Wells; Michael R Loken; Theresia M Westers
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

View more
  225 in total

1.  Persistent polyclonal B-cell lymphocytosis: extensively proliferated CD27+IgM+IgD+ memory B cells with a distinctive immunophenotype.

Authors:  M A Berkowska; C Grosserichter-Wagener; H J Adriaansen; D de Ridder; K P Mirani-Oostdijk; H J Agteresch; S Böttcher; A Orfao; J J M van Dongen; M C van Zelm
Journal:  Leukemia       Date:  2014-02-19       Impact factor: 11.528

2.  Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma.

Authors:  L Giaccone; L Brunello; M Festuccia; M Gilestro; E Maffini; F Ferrando; E Talamo; R Passera; M Boccadoro; P Omedè; B Bruno
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

3.  How to manage mantle cell lymphoma.

Authors:  M Dreyling; S Ferrero; O Hermine
Journal:  Leukemia       Date:  2014-05-23       Impact factor: 11.528

4.  Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Authors:  Maryalice Stetler-Stevenson; Bruno Paiva; Lloyd Stoolman; Pei Lin; Jeffrey L Jorgensen; Alberto Orfao; Jacques Van Dongen; Andy C Rawstron
Journal:  Cytometry B Clin Cytom       Date:  2015-07-06       Impact factor: 3.058

5.  Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.

Authors:  Wouter B L van den Bossche; Anne Kleijn; Charlotte E Teunissen; Jane S A Voerman; Cristina Teodosio; David P Noske; Jacques J M van Dongen; Clemens M F Dirven; Martine L M Lamfers
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

6.  Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.

Authors:  K Nowek; S M Sun; L Bullinger; E M J Bindels; C Exalto; M K Dijkstra; K van Lom; H Döhner; S J Erkeland; B Löwenberg; M Jongen-Lavrencic
Journal:  Leukemia       Date:  2015-07-15       Impact factor: 11.528

Review 7.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

8.  A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia.

Authors:  Anna Kalff; Tiffany Khong; Meaghan Wall; Malgorzata Gorniak; Sridurga Mithraprabhu; Lynda J Campbell; Andrew Spencer
Journal:  Haematologica       Date:  2014-11-07       Impact factor: 9.941

9.  Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Authors:  Theresia M Westers; Eline M P Cremers; Uta Oelschlaegel; Ulrika Johansson; Peter Bettelheim; Sergio Matarraz; Alberto Orfao; Bijan Moshaver; Lisa Eidenschink Brodersen; Michael R Loken; Denise A Wells; Dolores Subirá; Matthew Cullen; Jeroen G Te Marvelde; Vincent H J van der Velden; Frank W M B Preijers; Sung-Chao Chu; Jean Feuillard; Estelle Guérin; Katherina Psarra; Anna Porwit; Leonie Saft; Robin Ireland; Timothy Milne; Marie C Béné; Birgit I Witte; Matteo G Della Porta; Wolfgang Kern; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

10.  Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.

Authors:  Leonor Senent; Leonor Arenillas; Elisa Luño; Juan C Ruiz; Guillermo Sanz; Lourdes Florensa
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.